1. Home
  2. MEIP vs CYCU Comparison

MEIP vs CYCU Comparison

Compare MEIP & CYCU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • CYCU
  • Stock Information
  • Founded
  • MEIP 2000
  • CYCU N/A
  • Country
  • MEIP United States
  • CYCU United States
  • Employees
  • MEIP N/A
  • CYCU N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • CYCU
  • Sector
  • MEIP Health Care
  • CYCU
  • Exchange
  • MEIP Nasdaq
  • CYCU Nasdaq
  • Market Cap
  • MEIP 13.3M
  • CYCU 13.1M
  • IPO Year
  • MEIP 2003
  • CYCU N/A
  • Fundamental
  • Price
  • MEIP $2.53
  • CYCU $0.35
  • Analyst Decision
  • MEIP Hold
  • CYCU
  • Analyst Count
  • MEIP 1
  • CYCU 0
  • Target Price
  • MEIP N/A
  • CYCU N/A
  • AVG Volume (30 Days)
  • MEIP 21.5K
  • CYCU 1.8M
  • Earning Date
  • MEIP 05-13-2025
  • CYCU 06-06-2025
  • Dividend Yield
  • MEIP N/A
  • CYCU N/A
  • EPS Growth
  • MEIP N/A
  • CYCU N/A
  • EPS
  • MEIP N/A
  • CYCU N/A
  • Revenue
  • MEIP N/A
  • CYCU $17,398,680.00
  • Revenue This Year
  • MEIP N/A
  • CYCU N/A
  • Revenue Next Year
  • MEIP N/A
  • CYCU N/A
  • P/E Ratio
  • MEIP N/A
  • CYCU N/A
  • Revenue Growth
  • MEIP 33.76
  • CYCU N/A
  • 52 Week Low
  • MEIP $1.46
  • CYCU $0.26
  • 52 Week High
  • MEIP $4.10
  • CYCU $10.99
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 78.43
  • CYCU N/A
  • Support Level
  • MEIP $2.21
  • CYCU N/A
  • Resistance Level
  • MEIP $2.95
  • CYCU N/A
  • Average True Range (ATR)
  • MEIP 0.15
  • CYCU 0.00
  • MACD
  • MEIP 0.05
  • CYCU 0.00
  • Stochastic Oscillator
  • MEIP 81.48
  • CYCU 0.00

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About CYCU Cycurion Inc. Common Stock

Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).

Share on Social Networks: